Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379631 | 0.97 | NSD2 (0.35) | MAPK1NSD2KDM4EHTTGLA | |
| SCHEMBL30932816 | 0.97 | NSD2 (0.35) | MAPK1NSD2KDM4EHTTGLA | |
| SCHEMBL581560 | 0.93 | MAPK1 (0.32) | MAPK1NSD2KDM4EACHEMEN1 | |
| SCHEMBL30932858 | 0.84 | NSD2 (0.31) | MAPK1NSD2 | |
| SCHEMBL13534296 | 0.84 | ACHE (0.34) | MAPK1NSD2ACHEMEN1KMT2A | |
| SCHEMBL1205725 | 0.79 | GOT1 (0.41) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6932370 | 0.79 | ALDH1A1 (0.33) | KDM4EHTTGLAALDH1A1 | |
| SCHEMBL13534066 | 0.79 | ACHE (0.33) | MAPK1ACHEMEN1KMT2ABPTF | |
| SCHEMBL30932856 | 0.79 | — | — | |
| SCHEMBL24925903 | 0.75 | NOS3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53034785-A | — | — | None | — | — | JP | disclosed |
| EP-4574821-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3893889-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2026-01-01 | — | — | US | disclosed |
| EP-4655287-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4574821-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-1999036407-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM. CO., LTD. (KR) | 1999-07-22 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| EP-0099081-B1 | 6-SUBSTITUTED TETRAHYDROIMIDAZO(2,1-A)-PHTHALAZINES | THE DOW CHEMICAL COMPANY (US) | 1986-09-03 | — | — | EP | disclosed |
| EP-0029130-B1 | 3,6,7,8-SUBSTITUTED-S-TRIAZOLO(4,3-B)-PYRIDAZINES, THEIR PREPARATION AND COMPOSITIONS COMPRISING THEM | THE DOW CHEMICAL COMPANY (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4526890-A | Respiratory system disorders | THE DOW CHEMICAL COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0099081-A2 | 6-Substituted tetrahydroimidazo(2,1-a)-phthalazines | THE DOW CHEMICAL COMPANY (US) | 1984-01-25 | — | — | EP | disclosed |
| US-4391807-A | 6-Substituted tetrahydroimidazo[2,1-a]phthalazines and use as bronchodilators | THE DOW CHEMICAL COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0029130-A1 | 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them | THE DOW CHEMICAL COMPANY (US) | 1981-05-27 | — | — | EP | disclosed |
| JP-S5334785-A | 1-SUBSTITUTED-4-HALOGENO-5, 6, 7, 8-TETRAHYDROPHTHALAZINES | MITSUBISHI CHEM IND LTD | 1978-03-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, ADRB1 | MAPK1 736/4885NSD2 4644/4885KDM4E 4460/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | MAPK1 1708/4885NSD2 4295/4885KDM4E 2373/4885 |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | MAPK1 751/4885NSD2 3910/4885KDM4E 3235/4885 |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | MAPK1 751/4885NSD2 3910/4885KDM4E 3235/4885 |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | MAPK1 751/4885NSD2 3910/4885KDM4E 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.